
|Articles|November 3, 2015
ICON Partners with iCardiac On Phase I
Advertisement
ICON announced that its clinical research unit in San Antonio is a certified and preferred site in iCardiac’s Early Precision QT Program. The certification enables ICON to offer iCardiac’s Early Precision QT® services for evaluating the cardiac safety of new compounds in Phase I clinical trials. More accurate early QT studies may eliminate the need for later stage TQT studies, potentially saving costs.
Read
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Drug Repurposing Through AI-Driven In-Silico Clinical Trials
2
Balancing Innovation and Compliance under New GCP Guidelines
3
Obesity Trials: Scaling Operations for High-Demand Therapeutics
4
Former FDA Commissioners Warn New Vaccine Policies Could Undermine Longstanding Regulatory Framework
5






.png)



.png)



.png)
.png)
